[Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer
C H
CH
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000191:economics; D002318:Cardiovascular Diseases / Q000139:chemically induced; D000068579:Celecoxib; D003111:Colonic Polyps / Q000517:prevention & control; D003365:Costs and Cost Analysis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000191:economics; D004335:Drug and Narcotic Control; D005858:Germany; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000191:economics; D008134:Long-Term Care; D015337:Multicenter Studies as Topic; D011720:Pyrazoles / Q000009:adverse effects* / Q000191:economics; D016032:Randomized Controlled Trials as Topic; D012170:Retinal Vein Occlusion / Q000139:chemically induced*; D012306:Risk; D055502:Secondary Prevention; D013449:Sulfonamides / Q000009:adverse effects* / Q000191:economics; D013450:Sulfones / Q000009:adverse effects* / Q000191:economics; D014481:United States; D014786:Vision Disorders / Q000139:chemically induced*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib